Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07744971
Active, not recruiting Not applicable

Comparison of Four Qualia Sleep Formulations on Sleep Quality : An Open-label 4-arm Pilot Study

NCT07744971 · tracked via the Priya Life Science USA tracker
Sponsor
Qualia Life Sciences
Phase
Not applicable
Started
2026-09-12
Last updated
2026-10-05

Condition(s) studied

Sleep Quality

Investigational drug(s) / intervention(s)

Qualia Sleep Formula AQualia Sleep Formula BQualia Sleep Formula CQualia Sleep Formula D

Qualia Sleep Formula A: Oral Capsules. Dosage: 2 capsules once daily at night, 30-60 minutes before bed, for 28 days.

Qualia Sleep Formula B: Oral capsules. Dosage: 2 capsules once daily at night, 30-60 minutes before bed, for 28 days.

Qualia Sleep Formula C: Oral capsules. Dosage: 2 capsules once daily at night, 30-60 minutes before bed, for 28 days.

Qualia Sleep Formula D: Oral capsules. Dosage: 2 capsules once daily at night, 30-60 minutes before bed, for 28 days.

Study summary

This is a randomized, open-label, 4-arm pilot study designed to evaluate the efficacy and tolerability of four Qualia Sleep formulations (Formulas A, B, C, and D) in healthy adults aged 18 years and older who report poor sleep quality. The investigational products are encapsulated dietary supplements intended to support sleep quality and satisfaction. Approximately 100 participants will be allocated to one of four arms (n≈25 per arm) and will take 2 capsules of their assigned Qualia Sleep formula once daily for 28 consecutive days, administered 30-60 minutes before bedtime. The primary objective is to assess changes in sleep quality and satisfaction from baseline to Day 28 using the PROMIS Sleep Disturbance - Short Form 8b, with secondary outcomes including sleep-related impairment, pre-sleep arousal, and overall safety and tolerability. All study data, including self-reported sleep and safety questionnaires, will be collected electronically via secure links; there are no in-person visits or clinic-based assessments.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: * Healthy female and male adults aged 18 years and older with poor sleep quality. * A raw score ≥25 on the PROMIS Sleep Disturbance - Short Form questionnaire (preference given to participants with a higher score). * Can read and write English. * Provide voluntary, written, informed consent to participate in the study. * Agree to provide a valid cell phone number and are willing to receive communications through text. * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. * Willing to complete questionnaires, records, and diaries associated with the study. Exclusion criteria: * Women who are pregnant, breastfeeding, or planning to become pregnant during the trial. * Known food intolerances/allergy to any ingredients in the product. * Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer. * Having had a significant cardiovascular event in the past 6 months. * Taking any of the following medications, or on immunosuppressive therapy: * Psychiatric or neurological medications - including antidepressants (e.g., MAO inhibitors, SSRIs) and anxiolytics * Sleep medications - sedatives, hypnotics, benzodiazepines, dual orexin receptor antagonists, melatonin receptor agonists * Individuals who were deemed incompatible with the test protocol. * Adults lacking capacity to consent. * Unable to read and understand English.

Primary outcome measure(s)

  • Change from baseline in PROMIS Sleep Disturbance v1.0 Short Form 8b (PROMIS-SD) score — Baseline to Day 28
    Change from baseline to day 28 in PROMIS-SD scores across all participants using each formulation. The 8-item questionnaire assesses self-reported perceptions of sleep quality, sleep depth and restoration, and difficulties and dissatisfaction with sleep during the past 7 days. Total raw score ranges from 8 to 40, with higher scores indicating greater sleep disturbance.

Trial sites (1)

FacilityCityRegionStatus
Qualia Life Sciences Carlsbad California

More Qualia Life Sciences trials in the USA

Efficacy of Qualia Testosterone+ on Testosterone Levels in Adult Males Recruiting
Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life Recruiting
An Open-Label, Two-Arm Pilot Study of the Tolerability, Consumer Acceptability, and Exploratory Well-Being Outcomes of a Multi-Ingredient Protein Formula in Two Flavors in Healthy Adults Recruiting
The Impact of Qualia Vitamin C+ on Individuals With Suboptimal and Adequate Vitamin C Levels Recruiting
An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines Starting soon

Other trials for the same condition

The Effects of a Nutritional Supplement on Sleep Quality Recruiting
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus Active, not recruiting
Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07744971 on ClinicalTrials.gov ↗ ← All trials in the USA